RESULTS
tumor, abnormal tumor, lymphadenopathy
TUMOR, RECRUITMENT, LYMPHADENOPATHY
Among 316 patients in the study, a total of 282 tests were ordered that were not indicated in SCP recommendations (Figure Results of adjudication by chart review across both sites (Age < 50 at diagnosis or dense/heterogeneous tissue (15, 71%)Recommended follow‐up (2, 10%)Workup for symptoms (1, 5%)Symptoms (1, 9%)Surveillance (4, 36%)Assess response to radiation therapy (1, 9%)Follow‐up of previous radiographic abnormality (5, 45%)Symptoms (1, 9%)Elevated tumor markers (3, 27%) Surveillance (1, 9%)Work up for symptoms (5, 63%)Follow‐up of previous radiographic abnormality (1, 13%)Surveillance (1, 13%)Chronic symptoms (1, 13%)Follow‐up of previous radiographic abnormality (3, 33%)Elevated CEA or lymphadenopathy (2, 22%)
Abbreviations: ACR, American College of Radiology; CEA, carcinoembryonic antigen; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; PSA, prostate‐specific antigen.The majority of testing consistent with overuse was related to tumor markers (78/98, 80%) and subsequent imaging that was ordered to evaluate abnormal tumor marker values (3/98, 3%). Additionally, the majority of testing consistent with overuse was breast cancer‐related testing across recruitment sites (93/98, 95%). There was no significant difference in the incidence of overuse tests between SCP delivery study arms (